THIS SHARE WILL BE WORTH 3.00 IN 2009

Protherics PLC
27 November 2006

Protherics PLC

Protherics' DigiFabTM to replace Digitalis Antidot(R) in Europe


London, UK; Brentwood, TN, US: 27 November 2006 - Protherics PLC ('Protherics'
or the 'Company'), the international biopharmaceutical company focused on
critical care and cancer, today announces the transfer of market rights for
Digitalis Antidot(R) from Roche to Protherics, with the intention of replacing
Roche's Digitalis Antidot(R) in the market with Protherics' own digitalis
antidote DigiFabTM from early 2007.

Roche's Digitalis Antidot(R) is currently approved in France, Germany and
Switzerland. Protherics has acquired the market rights for Digitalis Antidot(R)
for a small undisclosed cash consideration, and is working with Roche to
facilitate the smooth transition in the market from Digitalis Antidot(R) to
DigiFabTM.

DigiFabTM is an ovine derived Fab preparation for the treatment of digoxin
toxicity which can have severe effects on the heart and central nervous system,
sometimes leading to death. It is currently licensed by the US Food and Drug
Administration for the treatment of patients with life-threatening or
potentially life-threatening digoxin toxicity or overdose. Marketing
authorisation will be sought in major European countries, including France,
Germany, Spain and Italy, following grant of approval in the UK, expected early
in 2007. Protherics will continue to make DigiFabTM available on a named
patient basis.

DigiFabTM will be marketed in most mainland European countries by Protherics'
licensee, Beacon Pharmaceuticals. Protherics will be directly responsible for
marketing and sales in Germany, one of the major European markets, as well as in
the Nordic countries.

Andrew Heath, Chief Executive of Protherics said:

'Protherics' goal is to become the global market leader in the anti-digoxin
antibody market. We are pleased to be co-operating with Roche in arranging for
a smooth market transition from Digitalis Antidot(R) to DigiFabTM in order to
ensure continued patient care for this potentially life-threatening condition.'

Eugene Tierney, Business Director at Roche said:

'Roche has been looking for a company that can take over its digitalis antidote
business, to ensure that it remains available for patients to treat
intoxication. We are pleased that Protherics, a company experienced in that
business, will be supplying the market.'





For further information please contact:


Protherics
Andrew Heath, CEO +44 (0) 20 7246 9950
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Saul Komisar, President Protherics Inc +1 615 327 1027

Financial Dynamics - press enquiries
London: Ben Atwell, David Yates, Anna Keeble +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600

I know it's still early, but I would have expected the sp to have moved up at least 5p on the news, especially after its dip that was overdone a couple of weeks ago.
I am sure the institutions will be buying this week.
Unfortunately, no spare cash to top up.
I wonder if Astrazeneca and Roche will view Protherics as an even more R+D productive target.
The competition in the pharmaceutical world is strong. If one company gets any inkling of the other sniffing around, you never know.
I am a strong believer in PTI as a future strong player in its field.
I hope that they stay independent.
But due to consolidation in the drugs market, you never know.

Finally decided to buy more after selling a far more risky share.
(Now watch this dip and my sell PET fly).
Looking to the mid to long term on this as PTI is a very solid, cash secure company with exciting, products and R+D base.

Typical, I increase my holdings and the following day a big drop for no apparent reason.
Good job I don't tip horses.
Only comfort is the whole sector is well down.

Aviva plc now hold 31,441,191 ordinary shares.
This notification follows the purchase of 105,500 ordinary shares on 27 November
2006 representing 0.04% of the issued share capital of the Company.
Always nice to see the institutions buying.

3p down today to 64p...don't look good now...on the sharp decline slope.

For full article see link.
Could see several smaller biotechnology companies, taken over in the next year.
Hopefully PTI will be looked at for more dual licencing, and not a takeover.


The Times December 05, 2006
Big hole in development pipeline
Robin Pagnamenta: Analysis

Pfizers pipeline was already viewed as weak, but the company now has little choice but to use some of its $17 billion cash pile to acquire other companies and potential drug candidates.

However, competition is likely to be intense as several other big drug groups are facing similar problems at the moment. AstraZeneca, GlaxoSmithKline and others are keen to make acquisitions and are paying big premiums for interesting biotechnology companies.

http://www.timesonline.co.uk/newspaper/0,,2740-2487079,00.html.

Whichever way it goes it's good news for companies like PTI.

Results out.

Apart from the odd hiccup, which investors in companies such as Protherics, should expect, the future looks very rosy indeed.

Three agreements to expand its development pipeline in its core franchises of critical care and cancer. Placing and Open Offer (the 'Placing and Open Offer'), at an issue price of 65 pence per share.
The Overview of the Transactions, looks good, lets hope the offer is nicely priced.
Revenue increased slightly. R@D increased vastly.
Strong cash position at end of period of 17.9 million.
Soon know how the market looks at it. The institutions may bide their time or step in prior to any placing. Would be nice to see them increase their holdings via the placing and before.

Re the cash call.

Whenever I see a company looking for further funding, I pay great detail to the reason.
If it is just to keep the company afloat, then usually it's a bad call.
Protherics are cash sound, so any increased funding in those circumstances is for a sound reason. It is not required for survival.
In my opinion, this cash call is for a very good reason, increased R@D and to push production and sales of existing products.
PTI have a very good product base already earning. They also have an excellent cache of products in varying stages of development, many being fated by the big companies that are looking to increase their product base.
The cash call IS fairly large with a proposed share issue of about 1 fifth of the total shares already in issue.
This to me says they are looking at a bigger picture of development for the next 2 to 5 years.
Yes, of course the shares will be diluted, but if the issue is set to us private investors at a good offer ratio, it may not drop the sp too much, after of course allowing for the dilution sp reduction.
Protherics management has shown consistently good management skills for many years now and as a holder of this share for a considerable time, I have faith in their decisions.
This faith is not blind, it is there because they have given me no reasons to doubt. I doubt that they will be looking at further calls for 2007-2008, as they have presumably judged the amount required with this call to see them through at least the next 2 to 3 years.
I am looking at a steady sp for the coming year.
I am then looking at a steady climbing sp at end 2007, into 2008.
The above is obviously my opinion, so could be totally wrong.
Greek.

Seems sound to me greekman.

Queen1,

Lets hope the market over the next few weeks takes the same view as we have.

Greekman - I hope you are right I am losing my nerve.
I wil support the new shares - lets face it 65p must be rock bottom but I am getting scared. Keep the fath.

Hang inthere transco. Fortune favours the brave, and all the jazz!

Hope I am not jinxing the sp but with an increase of 3.99% on an average volume, against a sector increase of .03%, there may be another after market close release re institutional buying. Can't see any other reason for it to be climbing.

In the cash call statement it stated that one of the reasons was a "Proposed In-licensing of intellectual property from Glenveigh
Pharmaceuticals LLC".

Note the word PROPOSED.

In an article released 2:57 PM CST Thursday in The Nashville Business Journal it states.

The company also has signed licensing deals with Glenveigh Pharmaceuticals, a North Carolina company that focuses on pregnancy-related drugs, and Advanced In Vitro Cell Technologies (AdvanCell), a company headquartered in Spain that develops cancer drugs.

Note. HAS SIGNED.

Maybe this is just a play on words by T N J, but I am wondering if this is part of the reason for the sp rise.
For the full article see link.

http://charlotte.bizjournals.com/nashville/stories/2006/12/04/daily29.html

A good 5 minute read. It shows the way the big drug conglomerates are courting the small bio companies.
Protherics is not mentioned, but must be up there in the sights of those multi million companies.
Licencing deals look the way forward.

Large pharmaceutical companies piggyback onto research, risk By Stephen Pounds
Palm Beach Post Staff Writer
Sunday, December 10, 2006.

"The big pharmaceutical companies recognize that biotechs are more willing to take risks and do research in areas that are more on the edge of science," said Jim Greenwood, president of the Washington, D.C.-based Biotechnology Industry Organization.

While Big Pharma's own drug discovery dwindles, investors in these behemoth companies worry about where sales will come from when a locker full of major medicines loses patent protection. Once the patents expire, drugs are quickly copied for generic sale by companies such as Miami's Ivax Corp., recently acquired by Israel's Teva Pharmaceutical Industries.

And it's not just Pfizer. Merck & Co.'s Fosamax, its $3 billion treatment for slowing bone loss, comes off patent in 2008; Singulair, the $3 billion drug for controlling chronic asthma, in 2010. Bristol-Myers Squibb loses the anti-clotting drug Plavix, the second largest-selling drug globally, in 2011. And Eli Lilly & Co. will lose exclusivity for Zyprexa, a schizophrenia drug worth $4 billion in annual sales, that same year, said Arthur Wong, an analyst with Standard & Poor's.

That's why Big Pharma mainly targets biotech companies, which have garnered a reputation for nimble scientific discovery.

For full article see link.

http://www.palmbeachpost.com/business/content/business/epaper/2006/12/10/a1f_bigpharma_1210.html

Just sent off a large cheque to take up my rights - I hope we come good!!

More sells than buys, on a narrow spread and up 3.25p (4.3%) against the sector (down around 4%). Someone accumulating for an institution increase perhaps.
Can't read anything else into Level 2.

PTI tipped in Money Observer supplement '2007 Wealth Creation Guide'. Under 'Shares Tipped For Big Gains in 2007' Mark Barnett of Invesco Perpetual says:-

"Protherics (PTI) 69p - This small biotech firm has seen share price falls due to delays in pipeline products. But a tie-up with AstraZeneca is worth the entire market capitalisation alone, so the rest of the business is being offered for zero value"

Let's hope he is right.

Well thats it for me pre Xmas, off out.
Merry Xmas to all.
Greek.